Show Summary Details
Page of

Subsequent management 

Subsequent management
Subsequent management

Samir Srivastava

and Gregory YH Lip

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 June 2021

Acute coronary syndrome patients have a high risk of recurrence of an ischaemic event.

Appropriate secondary prevention measures should be taken.

Aggressive risk factor management and pharmacotherapy can reduce the need for further percutaneous coronary interventional procedures.

Dual anti-platelet therapy is usually continued for up to 12 months (unless being considered for coronary artery bypass grafting); one agent remains life-long.

ACE inhibitors have an anti-atherogenic effect and should be used in patients with established atherosclerotic disease.

Blood pressure should ideally be less than 140/90 mmHg (130/80 in diabetics).

It is essential to address all lifestyle issues.

Subsequent PCI can be useful for alleviating cardiac ischaemic symptoms, but does not confer a mortality benefit and is not a superior strategy compared with medical therapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.